{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:08:04Z","timestamp":1772136484531,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-36864-w","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T20:17:37Z","timestamp":1769113057000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Benefit and risk associated with interleukin-6 receptor inhibitor administration during severe COVID-19: a retrospective multicentric study"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7349-6113","authenticated-orcid":false,"given":"Charl\u00e8ne","family":"Lef\u00e8vre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Th\u00e9o","family":"Funck-Brentano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9739-7950","authenticated-orcid":false,"given":"Marine","family":"Cachanado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0932-6739","authenticated-orcid":false,"given":"Alexia","family":"Plocque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9285-6203","authenticated-orcid":false,"given":"Ma\u00eblle","family":"Youinou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5179-7644","authenticated-orcid":false,"given":"Audrey","family":"Fels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3639-3849","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"P\u00e8ne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6862-8975","authenticated-orcid":false,"given":"Laurent","family":"Savale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9358-6922","authenticated-orcid":false,"given":"David","family":"Montani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6802-9545","authenticated-orcid":false,"given":"Olivier","family":"Voisin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0202-6736","authenticated-orcid":false,"given":"Flore","family":"Bintein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0438-5169","authenticated-orcid":false,"given":"Lucille","family":"Wildenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Philippe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4782-6734","authenticated-orcid":false,"given":"St\u00e9phane","family":"Legriel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3162-5033","authenticated-orcid":false,"given":"Nicolas","family":"Roche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0903-9828","authenticated-orcid":false,"given":"Pierre-R\u00e9gis","family":"Burgel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4055-617X","authenticated-orcid":false,"given":"Nicolas","family":"No\u00ebl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3093-1378","authenticated-orcid":false,"given":"Christophe","family":"Baillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1902-2624","authenticated-orcid":false,"given":"Jacques","family":"Duranteau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6373-8956","authenticated-orcid":false,"given":"Gilles","family":"Chatellier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7323-0742","authenticated-orcid":false,"given":"Francois","family":"Philippart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"36864_CR1","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","volume":"397","author":"O Abani","year":"2021","unstructured":"Abani, O. et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet 397, 1637\u20131645. https:\/\/doi.org\/10.1016\/S0140-6736(21)00676-0 (2021).","journal-title":"The Lancet"},{"key":"36864_CR2","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jama.2020.17021","volume":"324","author":"BM Tomazini","year":"2020","unstructured":"Tomazini, B. M. et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: The CoDEX randomized clinical trial. JAMA 324, 1307\u20131316. https:\/\/doi.org\/10.1001\/jama.2020.17021 (2020).","journal-title":"JAMA"},{"key":"36864_CR3","doi-asserted-by":"publisher","unstructured":"WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, et al (2020) Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA 324: 1330\u20131341 https:\/\/doi.org\/10.1001\/jama.2020.17023","DOI":"10.1001\/jama.2020.17023"},{"key":"36864_CR4","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.cell.2021.02.029","volume":"184","author":"JL Schultze","year":"2021","unstructured":"Schultze, J. L. & Aschenbrenner, A. C. COVID-19 and the human innate immune system. Cell 184, 1671\u20131692. https:\/\/doi.org\/10.1016\/j.cell.2021.02.029 (2021).","journal-title":"Cell"},{"key":"36864_CR5","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s12879-021-05945-8","volume":"21","author":"P Sabaka","year":"2021","unstructured":"Sabaka, P. et al. Role of interleukin 6 as a predictive factor for a severe course of Covid-19: retrospective data analysis of patients from a long-term care facility during Covid-19 outbreak. BMC Infect Dis 21, 308. https:\/\/doi.org\/10.1186\/s12879-021-05945-8 (2021).","journal-title":"BMC Infect Dis"},{"key":"36864_CR6","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1093\/cid\/ciaa449","volume":"71","author":"X Chen","year":"2020","unstructured":"Chen, X. et al. Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019. Clin Infect Dis 71, 1937\u20131942. https:\/\/doi.org\/10.1093\/cid\/ciaa449 (2020).","journal-title":"Clin Infect Dis"},{"key":"36864_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40265-022-01803-2","volume":"83","author":"A Plocque","year":"2023","unstructured":"Plocque, A. et al. Should we interfere with the interleukin-6 receptor during COVID-19: what do we know so far?. Drugs 83, 1\u201336. https:\/\/doi.org\/10.1007\/s40265-022-01803-2 (2023).","journal-title":"Drugs"},{"key":"36864_CR8","doi-asserted-by":"publisher","unstructured":"Ghosn L, Assi R, Evrenoglou T, et al (2023) Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev 6:CD013881. https:\/\/doi.org\/10.1002\/14651858.CD013881.pub2","DOI":"10.1002\/14651858.CD013881.pub2"},{"key":"36864_CR9","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1080\/22221751.2022.2059405","volume":"11","author":"S-Y Yu","year":"2022","unstructured":"Yu, S.-Y. et al. Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis. Emerg Microbes Infect 11, 1154\u20131165. https:\/\/doi.org\/10.1080\/22221751.2022.2059405 (2022).","journal-title":"Emerg Microbes Infect"},{"key":"36864_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0548","volume":"5","author":"AM Albuquerque","year":"2022","unstructured":"Albuquerque, A. M. et al. Mortality rates among hospitalized patients With COVID-19 infection treated with tocilizumab and corticosteroids: A Bayesian reanalysis of a previous meta-analysis. JAMA Netw Open 5, e220548. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.0548 (2022).","journal-title":"JAMA Netw Open"},{"key":"36864_CR11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nrd.2018.45","volume":"17","author":"C Garbers","year":"2018","unstructured":"Garbers, C., Heink, S., Korn, T. & Rose-John, S. Interleukin-6: designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov 17, 395\u2013412. https:\/\/doi.org\/10.1038\/nrd.2018.45 (2018).","journal-title":"Nat Rev Drug Discov"},{"key":"36864_CR12","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.immuni.2019.03.026","volume":"50","author":"S Kang","year":"2019","unstructured":"Kang, S., Tanaka, T., Narazaki, M. & Kishimoto, T. Targeting interleukin-6 signaling in clinic. Immunity 50, 1007\u20131023. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.026 (2019).","journal-title":"Immunity"},{"key":"36864_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature14228","volume":"519","author":"K Taniguchi","year":"2015","unstructured":"Taniguchi, K. et al. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature 519, 57\u201362. https:\/\/doi.org\/10.1038\/nature14228 (2015).","journal-title":"Nature"},{"key":"36864_CR14","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s40265-023-01870-z","volume":"83","author":"A Plocque","year":"2023","unstructured":"Plocque, A. & Philippart, F. Authors\u2019 reply to chia siang kow et al.: comment on: \u2018should we interfere with the interleukin-6 receptor during COVID-19: What Do We Know So Far?. Drugs 83, 647\u2013648. https:\/\/doi.org\/10.1007\/s40265-023-01870-z (2023).","journal-title":"Drugs"},{"key":"36864_CR15","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s40265-023-01869-6","volume":"83","author":"CS Kow","year":"2023","unstructured":"Kow, C. S., Ramachandram, D. S. & Hasan, S. S. Comment on: \u2018should we interfere with the interleukin-6 receptor during COVID-19: what do we know?\u2019. Drugs 83, 645\u2013646. https:\/\/doi.org\/10.1007\/s40265-023-01869-6 (2023).","journal-title":"Drugs"},{"key":"36864_CR16","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.cmi.2021.04.019","volume":"27","author":"IM Tleyjeh","year":"2021","unstructured":"Tleyjeh, I. M. et al. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update. Clin Microbiol Infect 27, 1076\u20131082. https:\/\/doi.org\/10.1016\/j.cmi.2021.04.019 (2021).","journal-title":"Clin Microbiol Infect"},{"key":"36864_CR17","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/qjmed\/hcab142","volume":"114","author":"T Avni","year":"2021","unstructured":"Avni, T. et al. Tocilizumab in the treatment of COVID-19-a meta-analysis. QJM 114, 577\u2013586. https:\/\/doi.org\/10.1093\/qjmed\/hcab142 (2021).","journal-title":"QJM"},{"key":"36864_CR18","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1002\/jmv.26509","volume":"93","author":"M Aziz","year":"2021","unstructured":"Aziz, M. et al. Efficacy of tocilizumab in COVID-19: A systematic review and meta-analysis. J Med Virol 93, 1620\u20131630. https:\/\/doi.org\/10.1002\/jmv.26509 (2021).","journal-title":"J Med Virol"},{"key":"36864_CR19","doi-asserted-by":"publisher","unstructured":"Bhimraj A, Morgan RL, Shumaker AH, et al (2022) Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin Infect Dis ciac724. https:\/\/doi.org\/10.1093\/cid\/ciac724","DOI":"10.1093\/cid\/ciac724"},{"key":"36864_CR20","doi-asserted-by":"publisher","first-page":"1700582","DOI":"10.1183\/13993003.00582-2017","volume":"50","author":"A Torres","year":"2017","unstructured":"Torres, A. et al. International ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)\/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociaci\u00f3n Latinoamericana del T\u00f3rax (ALAT). Eur Respir J 50, 1700582. https:\/\/doi.org\/10.1183\/13993003.00582-2017 (2017).","journal-title":"Eur Respir J"},{"key":"36864_CR21","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13613-018-0444-0","volume":"8","author":"M Leone","year":"2018","unstructured":"Leone, M. et al. Brief summary of French guidelines for the prevention, diagnosis and treatment of hospital-acquired pneumonia in ICU. Ann. Intensive Care 8, 104. https:\/\/doi.org\/10.1186\/s13613-018-0444-0 (2018).","journal-title":"Ann. Intensive Care"},{"key":"36864_CR22","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil, A. C. et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases Society of America and the American Thoracic Society. Clin Infect Dis 63, e61\u2013e111. https:\/\/doi.org\/10.1093\/cid\/ciw353 (2016).","journal-title":"Clin Infect Dis"},{"key":"36864_CR23","doi-asserted-by":"crossref","unstructured":"Calandra T, Cohen J, International Sepsis Forum Definition of Infection in the ICU Consensus Conference 2005 The international sepsis forum consensus conference on definitions of infection in the intensive care unit Crit Care Med 33 1538 1548","DOI":"10.1097\/01.CCM.0000168253.91200.83"},{"key":"36864_CR24","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1007\/s00134-012-2695-9","volume":"38","author":"A Tabah","year":"2012","unstructured":"Tabah, A. et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med 38, 1930\u20131945. https:\/\/doi.org\/10.1007\/s00134-012-2695-9 (2012).","journal-title":"Intensive Care Med"},{"key":"36864_CR25","doi-asserted-by":"publisher","first-page":"899","DOI":"10.14309\/ajg.0000000000001245","volume":"116","author":"L Laine","year":"2021","unstructured":"Laine, L. et al. ACG clinical guideline: upper gastrointestinal and ulcer bleeding. Am. J. Gastroenterol. 116, 899\u2013917. https:\/\/doi.org\/10.14309\/ajg.0000000000001245 (2021).","journal-title":"Am. J. Gastroenterol."},{"key":"36864_CR26","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1055\/a-1939-4887","volume":"54","author":"IM Gralnek","year":"2022","unstructured":"Gralnek, I. M. et al. Endoscopic diagnosis and management of esophagogastric variceal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 54, 1094\u20131120. https:\/\/doi.org\/10.1055\/a-1939-4887 (2022).","journal-title":"Endoscopy"},{"key":"36864_CR27","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1001\/jama.2018.5684","volume":"320","author":"N Sengupta","year":"2018","unstructured":"Sengupta, N. & Cifu, A. S. Management of patients with acute lower gastrointestinal tract bleeding. JAMA 320, 86\u201387. https:\/\/doi.org\/10.1001\/jama.2018.5684 (2018).","journal-title":"JAMA"},{"key":"36864_CR28","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/SHK.0000000000001769","volume":"56","author":"AE Stolarski","year":"2021","unstructured":"Stolarski, A. E., Kim, J., Zhang, Q. & Remick, D. G. Cytokine drizzle-the rationale for abandoning \u201ccytokine storm\u201d. Shock 56, 667\u2013672. https:\/\/doi.org\/10.1097\/SHK.0000000000001769 (2021).","journal-title":"Shock"},{"key":"36864_CR29","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/S2213-2600(20)30404-5","volume":"8","author":"DE Leisman","year":"2020","unstructured":"Leisman, D. E. et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir. Med. 8, 1233\u20131244. https:\/\/doi.org\/10.1016\/S2213-2600(20)30404-5 (2020).","journal-title":"Lancet Respir. Med."},{"key":"36864_CR30","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00048-2021","author":"JD Chalmers","year":"2021","unstructured":"Chalmers, J. D. et al. Management of hospitalised adults with coronavirus disease-19 (COVID-19): A European Respiratory Society living guideline. Eur. Respir. J. https:\/\/doi.org\/10.1183\/13993003.00048-2021 (2021).","journal-title":"Eur. Respir. J."},{"key":"36864_CR31","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrrheum.2017.83","volume":"13","author":"S Rose-John","year":"2017","unstructured":"Rose-John, S., Winthrop, K. & Calabrese, L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nat Rev Rheumatol 13, 399\u2013409. https:\/\/doi.org\/10.1038\/nrrheum.2017.83 (2017).","journal-title":"Nat Rev Rheumatol"},{"key":"36864_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.919489","volume":"13","author":"J-F Rossi","year":"2022","unstructured":"Rossi, J.-F. et al. Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling. Front Immunol 13, 919489. https:\/\/doi.org\/10.3389\/fimmu.2022.919489 (2022).","journal-title":"Front Immunol"},{"key":"36864_CR33","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.cmi.2020.10.021","volume":"27","author":"M Ripa","year":"2021","unstructured":"Ripa, M. et al. Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. Clin Microbiol Infect 27, 451\u2013457. https:\/\/doi.org\/10.1016\/j.cmi.2020.10.021 (2021).","journal-title":"Clin Microbiol Infect"},{"key":"36864_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.583897","volume":"7","author":"LM Kimmig","year":"2020","unstructured":"Kimmig, L. M. et al. IL-6 inhibition in critically Ill COVID-19 patients is associated with increased secondary infections. Front Med (Lausanne) 7, 583897. https:\/\/doi.org\/10.3389\/fmed.2020.583897 (2020).","journal-title":"Front Med (Lausanne)"},{"key":"36864_CR35","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00408-021-00451-9","volume":"199","author":"V Selvaraj","year":"2021","unstructured":"Selvaraj, V. et al. Tocilizumab in hospitalized patients with COVID-19: A meta analysis of randomized controlled trials. Lung 199, 239\u2013248. https:\/\/doi.org\/10.1007\/s00408-021-00451-9 (2021).","journal-title":"Lung"},{"key":"36864_CR36","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1038\/s41375-021-01264-8","volume":"35","author":"C-X Chen","year":"2021","unstructured":"Chen, C.-X. et al. Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19). Leukemia 35, 1661\u20131670. https:\/\/doi.org\/10.1038\/s41375-021-01264-8 (2021).","journal-title":"Leukemia"},{"key":"36864_CR37","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1136\/thoraxjnl-2020-215266","volume":"76","author":"FA Khan","year":"2021","unstructured":"Khan, F. A. et al. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. Thorax 76, 907\u2013919. https:\/\/doi.org\/10.1136\/thoraxjnl-2020-215266 (2021).","journal-title":"Thorax"},{"key":"36864_CR38","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1093\/infdis\/jiab328","volume":"224","author":"D Koeckerling","year":"2021","unstructured":"Koeckerling, D. & Barker, J. Accelerating the evolution of severe acute respiratory syndrome coronavirus 2: A risk of combining dexamethasone and tocilizumab for severe coronavirus disease 2019. J Infect Dis 224, 934\u2013937. https:\/\/doi.org\/10.1093\/infdis\/jiab328 (2021).","journal-title":"J Infect Dis"},{"key":"36864_CR39","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","volume":"384","author":"IO Rosas","year":"2021","unstructured":"Rosas, I. O. et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med 384, 1503\u20131516. https:\/\/doi.org\/10.1056\/NEJMoa2028700 (2021).","journal-title":"N Engl J Med"},{"key":"36864_CR40","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.eimc.2021.10.014","volume":"41","author":"R Ramos","year":"2023","unstructured":"Ramos, R. et al. COVID-19 associated infections in the ICU setting: A retrospective analysis in a tertiary-care hospital. Enferm Infecc Microbiol Clin 41, 278\u2013283. https:\/\/doi.org\/10.1016\/j.eimc.2021.10.014 (2023).","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"36864_CR41","doi-asserted-by":"publisher","DOI":"10.1097\/CCE.0000000000000343","volume":"3","author":"MC Vazquez Guillamet","year":"2021","unstructured":"Vazquez Guillamet, M. C. et al. Interleukin-6 trajectory and secondary infections in mechanically ventilated patients with coronavirus disease 2019 acute respiratory distress syndrome treated with interleukin-6 receptor blocker. Crit Care Explor 3, e0343. https:\/\/doi.org\/10.1097\/CCE.0000000000000343 (2021).","journal-title":"Crit Care Explor"},{"key":"36864_CR42","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s00134-021-06346-w","volume":"47","author":"N Buetti","year":"2021","unstructured":"Buetti, N. et al. COVID-19 increased the risk of ICU-acquired bloodstream infections: a case-cohort study from the multicentric OUTCOMEREA network. Intensive Care Med 47, 180\u2013187. https:\/\/doi.org\/10.1007\/s00134-021-06346-w (2021).","journal-title":"Intensive Care Med"},{"key":"36864_CR43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.55729\/2000-9666.1141","volume":"13","author":"H Liu","year":"2023","unstructured":"Liu, H. et al. Infectious complications after tocilizumab in patients with COVID: A real-world experience. J Community Hosp Intern Med Perspect 13, 11\u201319. https:\/\/doi.org\/10.55729\/2000-9666.1141 (2023).","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"36864_CR44","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","volume":"2","author":"G Guaraldi","year":"2020","unstructured":"Guaraldi, G. et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2, e474\u2013e484. https:\/\/doi.org\/10.1016\/S2665-9913(20)30173-9 (2020).","journal-title":"Lancet Rheumatol"},{"key":"36864_CR45","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","volume":"383","author":"JH Stone","year":"2020","unstructured":"Stone, J. H. et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med 383, 2333\u20132344. https:\/\/doi.org\/10.1056\/NEJMoa2028836 (2020).","journal-title":"N Engl J Med"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36864-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36864-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36864-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:39:06Z","timestamp":1770889146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36864-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["36864"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-36864-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6785789\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"30 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was carried out in accordance with the Declaration of Helsinki and French law. The TOCSIN study was approved by our institutional review board (GERM; IRB n\u00b000012157). Patients were informed about the study and their non-opposition to the collection and use of non-identifying data for research purposes was obtained. The processing of patient data complied with the reference methodology 004 of the French Commission Nationale de l\u2019Informatique et des Libert\u00e9s (French National Data Protection Agency).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"5978"}}